Cargando…
Development of a Nanoliposomal Formulation of Erlotinib for Lung Cancer and in vitro/In vivo Antitumoral Evaluation [Retraction]
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680674/ https://www.ncbi.nlm.nih.gov/pubmed/36425305 http://dx.doi.org/10.2147/DDDT.S398024 |
Ejemplares similares
-
Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation
por: Zhou, Xiao, et al.
Publicado: (2017) -
Development and Evaluation of in-situ Nasal Gel Formulations of Nanosized Transferosomal Sumatriptan: Design, Optimization, in vitro and in vivo Evaluation [Retraction]
Publicado: (2022) -
Retracted: Antitumor Effects of 10058-F4 and Curcumin in Combination Therapy for Pancreatic Cancer In Vitro and In Vivo
por: Healthcare Engineering, Journal of
Publicado: (2023) -
[Retracted] miR‑154 suppresses non‑small cell lung cancer growth in vitro and in vivo
por: Lin, Xingyu, et al.
Publicado: (2023) -
In vitro and in vivo Evaluation of Novel NGR-Modified Liposomes Containing Brucine [Retraction]
Publicado: (2022)